research Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease June 2025 in “Dermatopathology” Dupilumab and COVID-19 can worsen or trigger psoriasis.
research Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up August 2024 in “Clinical Cosmetic and Investigational Dermatology” Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
research Excessive hair growth in a patient with psoriatic erythroderma following secukinumab administration 3 citations , July 2018 in “European Journal of Dermatology” An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.
research A review of acitretin, a systemic retinoid for the treatment of psoriasis 75 citations , August 2005 in “Expert Opinion on Pharmacotherapy” Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.
research Psoriasis and Related Disorders 1 citations , March 2024 Psoriasis is a common, genetically influenced skin disease worsened by stress and lifestyle, but targeted treatments are promising.